NOT FOR DISTRIBUTION
Header cover image

Market Cap

€440.4m

Last Updated

2021/05/10 17:58 UTC

Data Sources

Company Financials +

Executive Summary

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has Nanobiotix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NANO is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: NANO's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-6.2%

NANO

-5.9%

FR Biotechs

0.6%

FR Market


1 Year Return

76.8%

NANO

28.7%

FR Biotechs

43.0%

FR Market

Return vs Industry: NANO exceeded the French Biotechs industry which returned 31.1% over the past year.

Return vs Market: NANO exceeded the French Market which returned 42% over the past year.


Shareholder returns

NANOIndustryMarket
7 Day-6.2%-5.9%0.6%
30 Day-11.8%-4.8%3.4%
90 Day-18.7%-16.9%11.3%
1 Year76.8%76.8%28.7%28.7%46.4%43.0%
3 Year-7.2%-7.2%-19.6%-19.7%28.7%18.3%
5 Year-32.0%-32.0%-47.1%-47.2%86.7%60.1%

Long-Term Price Volatility Vs. Market

How volatile is Nanobiotix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Nanobiotix undervalued compared to its fair value and its price relative to the market?

5.96x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NANO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NANO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NANO is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: NANO is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NANO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NANO is overvalued based on its PB Ratio (6x) compared to the FR Biotechs industry average (4.4x).


Future Growth

How is Nanobiotix forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

12.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NANO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NANO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NANO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NANO's revenue (57.1% per year) is forecast to grow faster than the French market (6.8% per year).

High Growth Revenue: NANO's revenue (57.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NANO is forecast to be unprofitable in 3 years.


Past Performance

How has Nanobiotix performed over the past 5 years?

-20.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NANO is currently unprofitable.

Growing Profit Margin: NANO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NANO is unprofitable, and losses have increased over the past 5 years at a rate of 20% per year.

Accelerating Growth: Unable to compare NANO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NANO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).


Return on Equity

High ROE: NANO has a negative Return on Equity (-47.67%), as it is currently unprofitable.


Financial Health

How is Nanobiotix's financial position?


Financial Position Analysis

Short Term Liabilities: NANO's short term assets (€125.2M) exceed its short term liabilities (€19.0M).

Long Term Liabilities: NANO's short term assets (€125.2M) exceed its long term liabilities (€44.5M).


Debt to Equity History and Analysis

Debt Level: NANO's debt to equity ratio (60.7%) is considered high.

Reducing Debt: NANO's debt to equity ratio has increased from 28.9% to 60.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NANO has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NANO has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 16.8% each year


Dividend

What is Nanobiotix current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NANO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NANO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NANO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NANO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NANO's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

Laurent Levy (47 yo)

18.17yrs

Tenure

€817,825

Compensation

Mr. Laurent Lévy, Ph.D. has been the President of the Executive Board at Nanobiotix S.A. since May 27, 2004 and its Chief Executive Officer since March 2003. Mr. Lévy has a thorough understanding of the te...


CEO Compensation Analysis

Compensation vs Market: Laurent's total compensation ($USD993.95K) is above average for companies of similar size in the French market ($USD557.80K).

Compensation vs Earnings: Laurent's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: NANO's management team is considered experienced (4.6 years average tenure).


Board Members

Experienced Board: NANO's board of directors are considered experienced (6.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 53.2%.


Top Shareholders

Company Information

Nanobiotix S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nanobiotix S.A.
  • Ticker: NANO
  • Exchange: ENXTPA
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €440.383m
  • Shares outstanding: 34.81m
  • Website: https://www.nanobiotix.com

Number of Employees


Location

  • Nanobiotix S.A.
  • 60 rue de Wattignies
  • Paris
  • Ile-de-France
  • 75012
  • France

Listings


Biography

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enha...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/10 17:58
End of Day Share Price2021/05/10 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.